Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomised Phase 2 Trial Investigating the Additional Benefit of Hydroxychloroquine(HCQ)to Short Course Radiotherapy (SCRT) in Patients Aged 70 Years and Older With High Grade Gliomas (HGG)

NCT01602588 is registered in ClinicalTrials.gov with University College, London as lead sponsor.

NCT NCT01602588
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01602588 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomised Phase 2 Trial Investigating the Additional Benefit of Hydroxychloroquine(HCQ)to Short Course Radiotherapy (SCRT) in Patients Aged 70 Years and Older With High Grade Gliomas (HGG)
Lead sponsor
University College, London
Phase
Phase 2
Overall status
Completed
Start date
May 31, 2013
Completion date
November 30, 2017
Enrollment
54 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

glioblastoma